FEED

#4995
ENvue Medical, Inc. - Common Stock
0.3 4 USD
-0.08%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
0.34
0.34
Intervallo Annuale
0.29
6.09
Variazione giornaliera
-8.11%
Variazione Mensile
+9.68%
Variazione di 6 mesi
-82.65%
Variazione Annuale
-92.64%
Chiusura Precedente
0.3 7
Open
0.3 4
Minimo
0.3 4
Massimo
0.3 4
Volume
2
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Envue Medical, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Envue Medical, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Envue Medical, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Envue Medical, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Envue Medical, Inc. quarterly report, Q2 FY2026
10-Q
Quarterly report, Q1 FY2026
Envue Medical, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Envue Medical, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Envue Medical, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
Envue Medical, Inc. annual report, FY2025
10-K
Current report, Q4 FY2025
Envue Medical, Inc. current report, Q4 FY2025
8-K

Envue Medical, Inc. current report, Q3 FY2026

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Envue Medical, Inc. on July 14, 2026. The report discloses significant changes to the composition of the Company's Board of Directors effective as of the filing date.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.

Material Changes

The primary material change reported is the restructuring of the Board of Directors:

  • Resignations: David Johnson and Nino Pionati voluntarily resigned from the Board. The Company states these resignations were not due to any disagreement regarding operations, policies, or practices.
  • Appointments: Zvi Joseph and Lior Buchman were appointed to fill the vacancies.
  • Committee Assignments:
    • Zvi Joseph: Audit Committee and Nominating and Corporate Governance Committee.
    • Lior Buchman: Audit Committee and Compensation Committee (serving as Chairman of the Compensation Committee).
    • Zeev Rotstein, M.D.: Appointed as Chair of the Nominating and Corporate Governance Committee and Chairman of the Board.

Guidance, Outlook, and Risks

The filing contains no financial guidance, outlook, or management commentary regarding future business performance. No specific risks or contingencies related to the resignations were disclosed, other than the standard statement that the departures were not caused by disagreements. The new directors will receive fees consistent with other non-executive directors, and no undisclosed transactions or arrangements were reported.

Key Facts for Investor Verification

  • Verify the professional backgrounds and potential conflicts of interest for new directors Zvi Joseph and Lior Buchman.
  • Confirm the strategic rationale for appointing Zeev Rotstein, M.D. as the new Chairman of the Board.
  • Review subsequent filings to ensure the resignations of Johnson and Pionati do not signal undisclosed operational issues.
  • Check for any related proxy statements or 10-Q/10-K filings that may provide context on the Board's composition relative to the Company's current financial status.